2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012, 62: 10-29.
3Tan A, Etit D, Bayol U, et al. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-l, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol, 2011, 15: 108-116.
4Hashimoto K, Morimoto A, Kato M, et al. Immunocytochemical analysis for differential diagnosis of thyroid lesions using liquid-based cytology. Nagoya J Med Sci, 2011, 73: 15-24.
5Abd-E1 Raouf SM, lbrahim TR. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derivedthyroid nodules. Pathol Res Pract, 2014, 210: 971-978.
6Cui W, Sang W, Zheng S, et al. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules. Clin Lab, 2012, 58: 673- 680.
7Ohta M, Ookoshi T, Naiki H, et al. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma. Pathol Int, 2015, 65: 119-125.
8Ronald AD, Ricardo VL, Philipp UH, et al. World Health Organization classification of tumors pathology and genetics of tumors of endocrine organs. United Kingdom and Europe: Oxford University Press, 2004: 57-66.
9Ozolins A, Narbuts Z, Strumfa 1, et al. Immunohistochemical expression of HBMEq, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Medicina (Kaunas), 2012, 48: 507- 5014.
10Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, 2006, 295: 2164-2167.
